[1]https://www.163.com/dy/article/GE7FEGCT0550EWRZ.html
[2]Han BH, SongYF, Li CG, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; Published online June 28, 2021.
[3]https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu
[4]Zou XH, Cao B. COVID-19 vaccines for children younger than 12 years: are we ready? Lancet Infect Dis. 2021;Published online June 28, 2021.
[5]Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021:NEJMoa2107456.
[6]https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf
[7]Al Kaabi N, Zhang Y, Xia S, et al.Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.JAMA. 2021: e218565.
https://jamanetwork.com/journals/jama/fullarticle/2780562
[8] https://m.huanqiu.com/article/41qqSkFsMpb